Who is sponsoring NCT05326126?

NCT05326126 is sponsored by Matteo Montorfano.

What drugs are being tested in NCT05326126?

Interventions in NCT05326126: coronary physiology.

What condition does NCT05326126 study?

NCT05326126 studies Severe Symptomatic Aortic Stenosis.

Is NCT05326126 still recruiting?

NCT05326126 is currently completed. Last updated 30 March 2026.

Last reviewed 2026-03-30 · How we verify

NCT05326126

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Microvascular Function in Patients Undergoing Transcatheter Aortic Valve Implant (TAVI) for Severe Symptomatic Aortic Stenosis: Association With Myocardial Fibrosis

Completed NA Last updated 30 March 2026

What this trial tests

NA trial testing coronary physiology in Severe Symptomatic Aortic Stenosis in 75 participants. Completed in 30 July 2025.

Timeline

8 July 2021

Primary endpoint
30 June 2025

30 July 2025

Quick facts

Lead sponsor	Matteo Montorfano
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	75
Start date	8 July 2021
Primary completion	30 June 2025
Estimated completion	30 July 2025
Sites	1 location across Italy

Drugs / interventions tested

coronary physiology

Conditions studied

Severe Symptomatic Aortic Stenosis — all drugs for Severe Symptomatic Aortic Stenosis →

Sponsor

Matteo Montorfano

Who can join

Adults 18 to 80, any sex, with Severe Symptomatic Aortic Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Microvascular function in patients undergoing Transcatheter Aortic Valve Implant (TAVI) for severe symptomatic aortic stenosis: association with myocardial fibrosis

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical Significance of Extracellular Volume of Myocardium (ECV) Assessed by Computed Tomography: A Systematic Review and Meta-Analysis.
Martuszewski A, Paluszkiewicz P, Poręba R, Gać P. · · 2025 · cited 5× · PMID 40142874 · DOI 10.3390/jcm14062066

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05326126 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Matteo Montorfano
Last refreshed: 30 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05326126.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing